Login to Your Account



Behind the alginate ball: Pneumonia bug in trouble as Aridis begins phase III

By Randy Osborne
Staff Writer

Wednesday, August 2, 2017

Aridis Pharmaceuticals Inc. kicked off a global pivotal study with Aerucin, a fully human monoclonal antibody (MAb) to treat acute pneumonia caused by gram-negative bacteria Pseudomonas aeruginosa.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription